FDA Approves Nypozi
FDA Approves Nypozi (filgrastim-txid), a Biosimilar to Neupogen
July 01, 2024 Tanvex BioPharma, Inc. (TWSE: 6541) announced that The U.S. Food and Drug Administration (FDA) had completed their review of our submission of Nypozi (TX01) and approved the biologics license application (BLA) on June 28, 2024.
“This milestone has moved the company beyond being a clinical/developmental stage company to a commercial company in the U.S.”, said Henry Chen, Chairman and CEO of Tanvex BioPharma, Inc. Nypozi (TX01), a proposed biosimilar to the reference product – Amgen’s NEUPOGEN® -- is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever.
According to data from IQVIA, filgrastim product sales were over to $400 million (USD) in the United States of America for the 12 months ended March, 2024. Tanvex’s Nypozi has been launched in Canada in January 2024.
Source: Tanvex BioPharma, Inc.
Posted: July 2024
Nypozi (filgrastim-txid) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
